GSK press releases Follow https://www.gsk.com/en-gb/media/press-releases/zejula-niraparib-is-the-first-and-only-once-daily-parp-inhibitor-fda-approved-as-a-first-line-monotherapy-maintenance-treatment-for-women-with-advanced-ovarian-cancer/ gsk.com
